Comparative Pharmacology
Head-to-head clinical analysis: LO ZUMANDIMINE versus LO OVRAL 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LO ZUMANDIMINE versus LO OVRAL 28.
LO-ZUMANDIMINE vs LO/OVRAL-28
Head-to-head clinical comparison of therapeutic indices and safety profiles.
LO-ZUMANDIMINE is a novel small molecule inhibitor of the mitogen-activated protein kinase (MAPK) pathway. It selectively binds to and inhibits the activity of MEK1 and MEK2, thereby blocking downstream phosphorylation of ERK1/2 and inhibiting cell proliferation in tumors with activated MAPK signaling.
Combination of norgestrel, a progestin, and ethinyl estradiol, an estrogen; suppresses gonadotropin secretion (FSH and LH) primarily via progestational activity, inhibiting ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial development, reducing implantation likelihood.
Treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutationOff-label: Investigational use in colorectal cancer with BRAF mutations
Prevention of pregnancyOral contraceptive
10-20 mg orally once daily, titrated to 40 mg daily based on response and tolerability.
One tablet orally once daily for 28 days. Each tablet contains 0.3 mg norgestrel and 0.03 mg ethinyl estradiol. Active tablets (21 days) followed by placebo tablets (7 days).
None Documented
None Documented
Terminal elimination half-life is 12–15 hours in adults with normal renal function. In elderly patients (>/=65 years) or those with creatinine clearance <30 mL/min, half-life extends to 20–28 hours, necessitating dose interval adjustment.
Norgestrel: 20-40 hours; Ethinyl estradiol: 13-27 hours. Steady-state achieved after 3-5 half-lives.
Primarily metabolized by CYP3A4 and CYP2C8 enzymes. Minor contributions from CYP1A2 and CYP2D6. Undergoes glucuronidation via UGT1A1.
Hepatic via CYP3A4 for ethinyl estradiol; norgestrel metabolized via reduction and conjugation.
Renal excretion accounts for 60% of total clearance (30% unchanged via glomerular filtration, 30% as inactive glucuronide conjugate). Biliary/fecal elimination contributes 35% (20% as parent drug, 15% as oxidative metabolites). The remaining 5% is eliminated via sweat and expired air.
Renal (approx. 50% as metabolites, <1% unchanged); biliary/fecal (approx. 50% as metabolites).
94–97% bound primarily to serum albumin (binding site II), with minor binding to alpha-1-acid glycoprotein. Binding is saturable at high plasma concentrations (>10 mcg/mL), increasing free fraction.
Norgestrel: 93-99% (primarily SHBG and albumin); Ethinyl estradiol: 97-98% (primarily albumin and SHBG).
Volume of distribution is 1.2–1.8 L/kg, indicating extensive tissue distribution. The central compartment Vd is 0.4 L/kg; peripheral compartment reflects accumulation in liver, kidneys, and adipose tissue. Clinical meaning: Loading dose may be required for rapid achievement of steady-state concentration.
Norgestrel: 3.0 L/kg; Ethinyl estradiol: 4.0 L/kg.
Oral bioavailability is 70–80% due to first-pass hepatic metabolism (CYP3A4). Rectal suppository bioavailability is 60–70%. Intramuscular bioavailability is >95%. Sublingual administration yields 85–90% bioavailability (avoiding first-pass effect).
Oral: Norgestrel 85-90%; Ethinyl estradiol 38-48% due to first-pass metabolism.
eGFR ≥30 mL/min: no adjustment; eGFR 15-29 mL/min: reduce dose to 10 mg daily; eGFR <15 mL/min: contraindicated.
No dosage adjustment required for renal impairment. However, use with caution in patients with renal dysfunction due to potential fluid retention.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 10 mg daily; Child-Pugh C: contraindicated.
Contraindicated in patients with Child-Pugh Class B or C cirrhosis. For Child-Pugh Class A, use with caution; limited data, but no specific dose adjustment recommended.
Children ≥6 years: 0.2 mg/kg/dose (max 10 mg) orally once daily; may increase to 0.4 mg/kg (max 20 mg) after 2 weeks.
Not indicated for use before menarche. For post-menarchal adolescents, the same dosing as adults: one tablet orally daily for 28-day cycles.
Initiate at 10 mg orally once daily; maximum 20 mg daily. Monitor renal function and avoid in patients with eGFR <30 mL/min.
Not indicated in postmenopausal women. No geriatric-specific dosing; not for use in elderly due to lack of need for contraception after menopause.
WARNING: SERIOUS SKIN REACTIONS AND OCULAR TOXICITY. LO-ZUMANDIMINE can cause severe dermatologic adverse reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Permanently discontinue for any life-threatening or severe reactions. Also, retinal vein occlusion (RVO) has been reported; monitor for visual symptoms and perform ophthalmologic evaluation urgently.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age and smoking intensity (especially in women over 35). Women should be strongly advised not to smoke.
Monitor for skin toxicity; interrupt or discontinue based on severity. Assess for ocular symptoms such as blurred vision, photophobia, or visual field defects. Avoid concurrent use with strong CYP3A4 inhibitors or inducers. May impair fertility. Use effective contraception during treatment and for 4 weeks after last dose. Cautious use in patients with hepatic impairment.
Thrombotic disorders (e.g., venous thromboembolism, stroke, myocardial infarction); hepatic neoplasia; hypertension; gallbladder disease; carbohydrate/lipid effects; ocular lesions; breakthrough bleeding; missed periods; ectopic pregnancy risk; lactation; depression.
Hypersensitivity to LO-ZUMANDIMINE or any excipients. Concomitant use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine). Active severe infection.
Thrombophlebitis or thromboembolic disorders; history of deep vein thrombosis or pulmonary embolism; cerebrovascular or coronary artery disease; known or suspected breast carcinoma; endometrial carcinoma or other estrogen-dependent neoplasia; undiagnosed abnormal genital bleeding; cholestatic jaundice of pregnancy or jaundice with prior pill use; hepatic adenoma or carcinoma; known or suspected pregnancy; hypersensitivity to any component.
Data Pending Review
Data Pending Review
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 and can increase drug levels. Take with food to reduce GI upset, but avoid high-fat meals which may decrease absorption.
No significant food interactions. Grapefruit juice does not notably affect ethinyl estradiol levels, but consistent intake is recommended to maintain uniform hormone levels. Avoid excessive alcohol consumption as it may impair liver function and alter hormone metabolism.
First trimester: Increased risk of congenital anomalies including neural tube defects and cleft palate based on animal studies; human data insufficient. Second/third trimesters: Possible fetal growth restriction and oligohydramnios; avoid use unless maternal benefit outweighs risk.
First trimester: No known association with major congenital anomalies, but small increased risk of cardiovascular defects and limb reduction defects reported in some studies. Second/third trimesters: Use not recommended due to potential adverse effects on fetal development including virilization of female fetus and hepatic adenoma; contraindicated in known pregnancy.
Excreted in human milk; M/P ratio unknown. Potential for adverse effects in nursing infant; manufacturer recommends discontinuing breastfeeding or drug.
Enters breast milk in small amounts; estrogen and progestin may reduce milk production and composition. M/P ratio not established. Generally avoided during breastfeeding due to theoretical risks; low-dose progestin-only contraception preferred.
No specific dose adjustment recommended; however, increased clearance in pregnancy may require dose titration based on therapeutic response. Monitor drug levels if available.
Contraindicated in pregnancy; no dose adjustments applicable as use is not recommended. Pharmacokinetic changes in pregnancy include increased clearance of ethinyl estradiol and norgestrel, but pregnancy contraindication precludes dose modification.
Category C
Category C
LO-ZUMANDIMINE is a prodrug that requires activation by CYP3A4; avoid concurrent use with strong CYP3A4 inhibitors or inducers. Monitor for QT prolongation, especially in patients with electrolyte abnormalities or pre-existing cardiac conditions. Administer with a full glass of water to reduce esophageal irritation.
LO/OVRAL-28 is a combination oral contraceptive containing norgestrel and ethinyl estradiol. It is indicated for pregnancy prevention. The 28-day regimen includes 21 active pills and 7 placebo pills. Counsel patients to take at the same time daily. Breakthrough bleeding is common in the first few cycles. If a dose is missed, follow the specific package instructions. Anti-infectives like rifampin may reduce efficacy; additional contraception is recommended.
Take this medication exactly as prescribed, at the same time each day.Do not consume grapefruit or grapefruit juice while taking this drug.Report any signs of irregular heartbeat, dizziness, or fainting immediately.Swallow tablets whole; do not crush or chew.Store at room temperature away from moisture and heat.
Take one pill daily at the same time each day.If you miss a pill, refer to the package insert for instructions; use backup contraception if needed.Common side effects include nausea, breast tenderness, and spotting, which usually improve after a few cycles.Smoking increases risk of serious cardiovascular side effects; do not smoke while taking this medication.Inform your healthcare provider if you have a history of blood clots, migraines with aura, or liver disease.